Top news of the week: 06.10.2021.
Startups
How a Venture Investor with a PhD in Genetics Helped This Biotech Firm Get Funded and Acquired
Jenny Rooke of Genoa Ventures used her reputation and technical expertise to make Intabio's innovative drug-analysis system a reality.
How a busy year for biotech IPOs measures up at the three-quarter mark
Drugmaker initial public offerings could break records set just a year ago. But valuations and stock performance have slipped from historic highs.
Biopharma Can Dispel the Fog of Data
Snthesis describes how data can be aggregated, connected, and harmonized to optimize workflows and reveal scientific insights.
Atlas Venture Announces $300 Million Second Opportunity Fund
Atlas Venture announces closing of $300 million second Opportunity Fund to invest growth capital in Atlas-backed biotech companies.
UBS clients raise $650 mln for biggest yet biotech impact fund
UBS's wealthy clients have raised $650 million for the biggest biotechnology impact fund ever, the Swiss bank said on Wednesday.
Aurion Biotech Industrializing Ophthalmologic Cell-Based Therapy
The company is focusing on improving shelf life and “turn-keying” treatment protocols.
Oxford Nanopore valued at $6.7 bln as shares soar in London debut
Shares of Oxford Nanopore Technologies soared more than 45% in their market debut on Thursday, giving the biotech group a market value of $6.7 billion and showing increased investor ...
Sweet Pharma Day’s aim: To find sixteen promising new Canadian biotech companies, dubbed the “Sweet 16”, who will be invited to present their project before a minimum of six large international pharmaceutical companies and leading venture funds for potential collaborations or partnerships.
Advantages of participating in Sweet Pharma Day > Unique interaction with large international pharmaceutical companies and venture capital firms > Direct networking with the …